公开(公告)号：US20190248872A1

公开(公告)日：2019-08-15

申请号：US16254114

申请日：2019-01-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ray Camphausen ,  Amna Saeed-Kothe ,  Jonathan Davis ,  Tracy S. Mitchell

IPC: C07K14/78 ,  C07K16/28 ,  C07K16/40 ,  C07K16/46 ,  C07K7/08 ,  C07K7/06 ,  G01N33/573 ,  C07K16/24 ,  C07K14/47

CPC classification number: C07K14/78 ,  A61K38/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/244 ,  C07K16/2863 ,  C07K16/40 ,  C07K16/46 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2318/20 ,  C07K2319/30 ,  G01N33/573 ,  G01N2333/948

Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.

公开(公告)号：US10214579B2

公开(公告)日：2019-02-26

申请号：US15257189

申请日：2016-09-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ray Camphausen ,  Amna Saeed-Kothe ,  Jonathan Davis ,  Tracy S. Mitchell

IPC: C07K14/78 ,  C07K14/47 ,  C07K7/06 ,  C07K7/08 ,  A61K38/00 ,  C07K16/24 ,  C07K16/28 ,  C07K16/40 ,  C07K16/46 ,  G01N33/573

Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10F3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.

公开(公告)号：US09416170B2

公开(公告)日：2016-08-16

申请号：US13757664

申请日：2013-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jonathan Davis ,  Dasa Lipovsek ,  Ray Camphausen

IPC: C40B40/10 ,  C07K14/78 ,  C07K14/47 ,  G01N33/68 ,  C12N15/10 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K14/78 ,  A61K38/00 ,  C07K14/47 ,  C07K16/241 ,  C07K16/244 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/2857 ,  C07K2317/92 ,  C07K2318/20 ,  C12N15/1062 ,  C40B40/10 ,  G01N33/68 ,  G01N33/6887

Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.